Literature DB >> 18766967

Primary cutaneous lymphomas: a population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003.

Marie Odile Riou-Gotta1, Evelyne Fournier, Isabelle Mermet, Fabien Pelletier, Philippe Humbert, Arlette Danzon, François Aubin.   

Abstract

Although primary cutaneous lymphomas (PCL) are the second most common group of extra-nodal non-Hodgkin lymphomas, few epidemiological data are available in the literature, and most of them are provided by large databases from population-based cancer registries in the US or patients attending a single institution. We conducted this study to investigate the epidemiological and clinical features of PCL diagnosed in the department of Doubs from 1980 to 2003. Data were collected from the Doubs cancer registry from 1980 to 2003. Seventy-one patients with PCL were investigated. 82% were cutaneous T-cell lymphoma (CTCL) and 18% were cutaneous B-cell lymphoma (CBCL). Among CTCL, mycosis fungoides (MF) represented 58% and Sezary syndrome 10%. The standardised incidence rate of PCL was 0.42 for 100 000 person-years and significantly increased from 0.21 in 1980-1984 to 0.70 in 2000-2003 (p <0.05). The incidence rate of CTCL was 0.34 for 100 000 person-year and significantly increased from 0.2 to 0.57 (p <0.05). For MF and CBCL, the incidence rates were 0.20 and 0.08, respectively and did not vary significantly from 1980-1984 to 2000-2003. Five-year survival was 64.5% for PCL patients similar to MF patients. Our results provide updated data on the incidence of PCL in France.

Entities:  

Mesh:

Year:  2008        PMID: 18766967     DOI: 10.1080/10428190802136368

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  [Primary cutaneous lymphoma-a case series of 163 patients].

Authors:  D Nashan; C M Friedrich; E Geissler; A Schmitt-Graeff; F Klein; F Meiss
Journal:  Hautarzt       Date:  2018-12       Impact factor: 0.751

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

3.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Authors:  Porcia T Bradford; Susan S Devesa; William F Anderson; Jorge R Toro
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

4.  Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Michelle A Jennings; David R Risser; Pamela Gangar; Elena Netchiporouk; Linda Moreau; Victor G Prieto; Denis Sasseville; Madeleine Duvic
Journal:  Cancer Med       Date:  2015-07-01       Impact factor: 4.452

5.  Characteristics of Cutaneous Lymphomas in Korea According to the New WHO-EORTC Classification: Report of a Nationwide Study.

Authors:  Jae Ho Han; Young-Hyeh Ko; Yun Kyung Kang; Wan-Seop Kim; Yoon Jung Kim; Insun Kim; Hyun-Jung Kim; Soo Kee Min; Chan-Kum Park; Chan-Sik Park; Bong-Kyung Shin; Woo Ick Yang; Young-Ha Oh; Jong Sil Lee; Juhie Lee; Tae Hui Lee; Hyekyung Lee; Ho Jung Lee; Yoon Kyung Jeon; Hee Jeong Cha; Yoo-Duk Choi; Chul Woo Kim
Journal:  Korean J Pathol       Date:  2014-04-28

6.  The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Authors:  Assia L Angelova; Mathias Witzens-Harig; Angel S Galabov; Jean Rommelaere
Journal:  Front Oncol       Date:  2017-05-12       Impact factor: 6.244

7.  Oral and Cutaneous Lymphomas other than Mycosis Fungoides and Sézary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities.

Authors:  Amparo Hernández-Salazar; Jorge Andrés García-Vera; Yann Charli-Joseph; Guadalupe Ortiz-Pedroza; Silvia Méndez-Flores; Rocío Orozco-Topete; Ana Lilia Morales-Leyte; Judith Domínguez-Cherit; Carmen Lome-Maldonado
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.